You need to be logged in to view this video
Lobe Sciences is Developing Psychedelic Derived Medicines for Neurologic and Brain Disease
Released on Thursday, November 10, 2022•BIOTECH
Lobe Sciences is a life sciences company focused on developing sub-psychedelic doses of psychedelic medicines targeting the 5-HT2A receptor. The company, through collaborations with industry-leading partners, is engaged in drug research and development using derivatives of psychedelic compounds to improve brain and mental health and wellness. Phil Young will provide an overview, scientific focus and development plans for 2023 and beyond and update the most recent exciting developments for their upcoming trials.
Philip Young
Lobe Sciences,
CEO and Director
Phil Young is an analytical and result-driven life sciences executive who has successfully managed public and private companies through product development, international growth, commercialization and M&A transactions. He has served as a director and chief executive officer for public companies for the past 20 years creating significant shareholder value.
Trending Now
Filter By Category
Filter By Keywords
Loading...